Anat Cell Biol.  2017 Mar;50(1):69-72. 10.5115/acb.2017.50.1.69.

Evaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor marker

• Heidari MH
• Movafagh A
• Abdollahifar MA
• Abdi S
• Barez MM
• Azimi H
• Moradi A
• Bagheri A
• Heidari M
• Hessam Mohseni J
• Tadayon M
• Mirsafian
• Ghatrehsamani M

• KMID: 2390428
• DOI: http://doi.org/10.5115/acb.2017.50.1.69

Abstract

Prostate cancer is the most common cancer type in men and is the second cause of death, due to cancer, in patients over 50, after lung cancer. Prostate specific antigen (PSA) is a widely used tumor marker for prostate cancer. Recently, PSA is discovered in non-prostatic cancer tissues in men and women raising doubts about its specificity for prostatic tissues. PSA exists in low serum level in healthy men and in higher levels in many prostate disorders, including prostatitis and prostate cancer. Thus, a supplementary tumor marker is needed to accurately diagnose the cancer and to observe the patient after treatment. Recently, soluble human leukocyte antigen-G (sHLA-G) has been introduced as a new tumor marker for different cancer types, including colorectal, breast, lung, and ovary. The present descriptive-experimental study was carried out including patients with malignant prostate tumor, patients with benign prostate tumor, and a group of health men as the control group, as judged by an oncologist as well as a pathologist. After sterile blood sampling, sHLA-G was measured by enzyme-linked immunosorbent assay in each group. The data was then analyzed using one-way ANOVA. P≤0.05 was considered as statistically significant. The results showed that the mean of sHLA-G level was high in patients. Also, it was found that there was a significant difference in sHLA serum level between the three groups. The data revealed that sHLA-G can be a novel supplementary tumor marker in addition to PSA to diagnose prostate cancer.

Keyword

Prostate; Tumor marker; sHLA-G

MeSH Terms

Breast
Cause of Death
Enzyme-Linked Immunosorbent Assay
Female
Humans
Leukocytes
Lung
Lung Neoplasms
Male
Ovary
Prostate*
Prostate-Specific Antigen
Prostatic Neoplasms*
Prostatitis
Sensitivity and Specificity
Prostate-Specific Antigen

Figure

• 

  Fig. 1 Mean and standard deviation of prostate specific antigen (PSA) level in malignant group, benign group, and control group (P<0.01).

• 

  Fig. 2 Mean and standard deviation of human leukocyte antigen-G (HLA-G) level in malignant group, benign group, and control group (*P<0.05).

• 

  Fig. 3 The comparison between the serum level of prostate specific antigen (PSA) and the serum level of soluble human leukocyte antigen-G (sHLA-G) (*P<0.05).

Reference

1. Miyahira AK, Lang JM, Den RB, Garraway IP, Lotan TL, Ross AE, Stoyanova T, Cho SY, Simons JW, Pienta KJ, Soule HR. Multidisciplinary intervention of early, lethal metastatic prostate cancer: report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. Prostate. 2016; 76:125–139.

2. Roussel B, Ouellet GM, Mohile SG, Dale W. Prostate cancer in elderly men: screening, active surveillance, and definitive therapy. Clin Geriatr Med. 2015; 31:615–629.

3. Carter HB. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale. BJU Int. 2013; 112:543–547.

4. Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P. Clinical Guidelines Committee of the American College of Physicians. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013; 158:761–769.

5. Murthy V, Rishi A, Gupta S, Kannan S, Mahantshetty U, Tongaonkar H, Bakshi G, Prabhash K, Bhanushali P, Shinde B, Inamdar N, Shrivastava S. Clinical impact of prostate specific antigen (PSA) inter-assay variability on management of prostate cancer. Clin Biochem. 2016; 49:79–84.

6. Ammannagari N, Javvaji C, Danchaivijitr P, George S. Dramatic PSA increase with tumor shrinkage after initiating degarelix in advanced prostate cancer. Clin Genitourin Cancer. 2016; 14:e123–e125.

7. van Iersel MP, Witjes WP, Thomas CM, Segers MF, Oosterhof GO, Debruyne FM. Review on the simultaneous determination of total prostate-specific antigen and free prostate-specific antigen. Prostate Suppl. 1996; 7:48–57.

8. Bjurlin MA, Rosenkrantz AB, Beltran LS, Raad RA, Taneja SS. Imaging and evaluation of patients with high-risk prostate cancer. Nat Rev Urol. 2015; 12:617–628.

9. Zigeuner R, Schips L, Lipsky K, Auprich M, Salfellner M, Rehak P, Pummer K, Hubmer G. Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies. Urology. 2003; 62:883–887.

10. Rouas-Freiss N, Moreau P, LeMaoult J, Carosella ED. The dual role of HLA-G in cancer. J Immunol Res. 2014; 2014:359748.

11. Zidi I, Ben Amor N. HLA-G regulators in cancer medicine: an outline of key requirements. Tumour Biol. 2011; 32:1071–1086.

12. Yie SM, Hu Z. Human leukocyte antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in human malignancies. Histol Histopathol. 2011; 26:409–420.

13. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science. 1990; 248:220–223.

14. LeMaoult J, Daouya M, Wu J, Loustau M, Horuzsko A, Carosella ED. Synthetic HLA-G proteins for therapeutic use in transplantation. FASEB J. 2013; 27:3643–3651.

15. Wang Y, Fan X, Li H, Lin Z, Bao H, Li S, Wang L, Jiang T, Fan Y, Jiang T. Tumor border sharpness correlates with HLA-G expression in low-grade gliomas. J Neuroimmunol. 2015; 282:1–6.

16. Guo ZY, Lv YG, Wang L, Shi SJ, Yang F, Zheng GX, Wen WH, Yang AG. Predictive value of HLA-G and HLA-E in the prognosis of colorectal cancer patients. Cell Immunol. 2015; 293:10–16.

17. Langat DK, Sue Platt J, Tawfik O, Fazleabas AT, Hunt JS. Differential expression of human leukocyte antigen-G (HLA-G) messenger RNAs and proteins in normal human prostate and prostatic adenocarcinoma. J Reprod Immunol. 2006; 71:75–86.